# Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

> **NCT06397222** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 23 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

- **DRUG:** Sin-Bev-SIRT

## Key facts

- **NCT ID:** NCT06397222
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06397222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06397222, "Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06397222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*